Home / Market News / Eli Lilly to reduce list price of Insulin Lispro injection by an additional 40% from Jan. 1, restoring it to 2008 levels

Eli Lilly to reduce list price of Insulin Lispro injection by an additional 40% from Jan. 1, restoring it to 2008 levels

Eli Lilly & Co. said Tuesday it is reducing the list price of Insulin Lispro Injection in the U.S. by another 40% effective Jan. 1, 2022, bringing the price down to 2008 levels. “Lilly’s Insulin Lispro Injection, 100 units/mL — first introduced at half the list price of branded Humalog(R) (insulin lispro injection, 100 units/mL) in 2019 — will now have a 70% lower list price than Humalog U-100,” the company said in a statement. People using any of Lilly’s insulin products can fill their monthly prescription for $35 through the Lilly Insulin Value Program, for those with commercial insurance or who are uninsured, while seniors can use a program that is part of Medicare Part D plans. “We hope this additional 40 percent cut can expand affordable insulin to more people with diabetes,” Lilly Chief Executive David Ricks said in a statement. Lilly shares were down 0.4% premarket.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Read Full Story